NO Cancer Research Results

NO, Nitric Oxide: Click to Expand ⟱
Source:
Type:
Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells.
The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment.
Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS).

– In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer.

• Expression Patterns in Tumors:
– Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment.

– Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation.
Scientific Papers found: Click to Expand⟱
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2/PTGS2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, VEGFR2/KDR/Flk1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27/CDKN1B↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
1177- Ash,    Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis
- in-vivo, EC, NA
TumVol↓, MMP2↓, MMP9↓, NF-kB↓, COX2/PTGS2↓, NO↓, IL1β↓, IL6↓,
1146- AsP,    Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms
- in-vivo, Nor, NA
TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,
2308- CUR,    Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells
- in-vitro, Liver, HepG2
GlucoseCon↓, lactateProd↓, ECAR↓, NO↓, ROS↑, HK2↓, PFK1↓, GAPDH↓, PKM2↓, LDHA↓, FASN↓, GLUT1↓, MCT1↓, MCT4↓, HCAR1↓, SDH↑, ChemoSen↑, ROS↑, BioAv↑, P53↑, NF-kB↓, pH↑,
6692- DFC,    Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity
- in-vivo, PC, Panc02
TumW↓, Apoptosis↑, VEGF↓, COX2/PTGS2↓, ARG1/2↑, TumCG↓, angioG↓, ARG↓, NO↓,
6328- DRE,    Hydroalcoholic extract of Taraxacum officinale induces apoptosis and autophagy in 4T1 breast cancer cells
- in-vitro, BC, 4T1
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, DNAdam↑, BAX↑, Bax:Bcl2↑, P53↑, Beclin-1/ATG6↑, ATG7↑, Bcl-2↓, NO↓,
6919- FIS,    Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells
TumCP↓, Inflam↓, NO↓, iNOS↓, COX2/PTGS2↓, IL6↓, TNF-α↓, NF-kB↓, p‑cJun↓,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2/PTGS2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
7242- Gink,  Cisplatin,    Ginkgetin reverses cisplatin resistance in cervical cancer by regulating the Nrf2/HO-1 signaling pathway to induce ferroptosis
- in-vitro, Cerv, HeLa
TumCP↓, NRF2↓, ROS↑, i-Iron↑, GSH↓, SOD↓, Catalase↓, lipid-P↑, ACSL4↑, NO↓, GPx4↓, Ferroptosis↑,
8184- LGE,    Cytotoxicity of citral against melanoma cells: The involvement of oxidative stress generation and cell growth protein reduction
- in-vitro, Melanoma, B16-BL6 - in-vitro, Nor, HaCaT
TumCP↓, ROS↑, DNAdam↑, P53↝, NO↓, NF-kB↓, ERK↓, Akt↓, selectivity↑,
3278- Lyco,    Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells
- in-vitro, Colon, SW480
TNF-α↓, IL1β↓, IL6↓, iNOS↓, COX2/PTGS2↓, PGE2↓, NO↓, NF-kB↓, JNK↓, Inflam↓, MPO↓,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
8425- OM,    Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production
- vitro+vivo, BC, MDA-MB-231
TumCCA↑, Apoptosis↑, E-cadherin↑, TumCMig↓, MMP2↓, MMP9↓, uPAR↓, ICAM-1↓, VEGF↓, p‑IκB↓, NF-kB↓, NO↓, TumCG↓, TumMeta↓,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
3380- QC,    Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases
- Review, Var, NA - Review, Park, NA - Review, AD, NA
JAK↓, STAT↓, Inflam↓, NO↓, COX2/PTGS2↓, CRP↓, selectivity↑, *neuroP↑, STAT3↓, cycD1/CCND1↓, MMP2↓, STAT4↓, JAK2↓, TumCP↓, Diff↓, *eff↑, *IL6↓, *TNF-α↓, *IL1β↓, *Aβ↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2/KDR/Flk1↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2/PTGS2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
1478- SFN,  acet,    Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells
- in-vitro, Nor, NA
eff↑, NO↓, iNOS↓, COX2/PTGS2↓, IL1β↓, ROS↓,
3310- SIL,    Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro
- in-vitro, Lung, A549
Inflam↓, MPO↓, NO↓, iNOS↓, ROS↓, MDA↑, SOD↑, Catalase↑, GPx↑, NRF2↑, HO-1↑, NADPH↑,
2427- Wog,    Anti-cancer natural products isolated from chinese medicinal herbs
- Review, Var, NA
NO↓, PGE2↓, COX2/PTGS2↓, Ca+2↑, mtDam↑, *toxicity↓, eff↑, eff↓,

Showing Research Papers: 1 to 20 of 20

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 20

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ARG↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Catalase↑, 2,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 3,   HO-1↑, 1,   i-Iron↑, 1,   Keap1↓, 1,   lipid-P↑, 2,   MDA↓, 1,   MDA↑, 1,   MPO↓, 2,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 3,   ROS↑, 8,   ROS⇅, 1,   SOD↓, 1,   SOD↑, 2,   Trx↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 2,   MPT↑, 1,   mtDam↑, 1,   SDH↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,   ATG7↑, 1,   CAIX/CA9↑, 1,   cMyc↓, 3,   ECAR↓, 1,   FASN↓, 2,   GAPDH↓, 1,   GlucoseCon↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   MCT4↓, 1,   NADPH↑, 1,   PFK1↓, 1,   PKM2↓, 1,   PPARγ↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 1,   Apoptosis↑, 6,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 5,   Casp9↑, 3,   cFLIP↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 3,   Diablo↑, 1,   Ferroptosis↑, 2,   iNOS↓, 7,   JNK↓, 1,   JNK↑, 2,   MAPK↑, 1,   Mcl-1↓, 2,   MCT1↓, 1,   oncosis↑, 1,   p27/CDKN1B↑, 2,   p38↓, 1,   p38↑, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   HSP27↝, 1,   HSP70/HSPA5↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 4,   DNArepair↑, 1,   DNMTs↓, 1,   HR↓, 1,   p16↑, 1,   P53?, 1,   P53↑, 5,   P53↝, 1,   cl‑PARP↑, 1,   PARP1↑, 1,   PCNA↓, 1,   RAD51↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 3,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   cycE1↓, 1,   P21↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cMET↓, 1,   Diff↓, 1,   EMT↓, 1,   ERK↓, 3,   p‑ERK↓, 2,   FOXM1↓, 1,   HDAC↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 4,   PTEN↑, 2,   STAT↓, 1,   STAT3↓, 5,   STAT4↓, 1,   TumCG↓, 3,   TumCG↑, 1,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↓, 1,   AntiAg↑, 1,   ARG1/2↑, 1,   Ca+2↑, 1,   CDK4/6↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↑, 3,   ITGB1↑, 1,   Ki-67↓, 1,   MMP1↓, 1,   MMP13↓, 2,   MMP2↓, 8,   MMP3↓, 2,   MMP7↓, 1,   MMP9↓, 7,   MMPs↓, 1,   N-cadherin↓, 1,   NCAM↑, 1,   PKCδ↓, 1,   Snail↓, 1,   TGF-β↓, 2,   TIMP2↑, 1,   Treg lymp↓, 1,   TSP-1↑, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 6,   TumMeta↓, 3,   TumMeta↑, 1,   Twist↓, 1,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EGFR↓, 3,   Hif1a↓, 4,   NO↓, 20,   VEGF↓, 8,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 11,   CRP↓, 2,   CXCR4↓, 1,   FOXP3↓, 1,   HCAR1↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 4,   IL6↓, 9,   IL8↓, 1,   Inflam↓, 5,   p‑IκB↓, 1,   JAK↓, 1,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 9,   NF-kB↑, 1,   NK cell↑, 1,   PGE2↓, 5,   T-Cell↑, 1,   Th1 response↑, 1,   TNF-α↓, 5,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 3,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 4,   Dose∅, 1,   eff↓, 1,   eff↑, 7,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   CRP↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   FOXM1↓, 1,   IL6↓, 9,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   ChemoSideEff↓, 1,   neuroP↑, 1,   OS↑, 1,   radioP↑, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 220

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   ROS↓, 1,   SOD↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 17

Scientific Paper Hit Count for: NO, Nitric Oxide
2 Fisetin
2 Quercetin
1 alpha Linolenic acid
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Ascorbyl Palmitate
1 Curcumin
1 Diclofenac
1 Dandelion Root
1 Ginkgetin
1 Cisplatin
1 Lemongrass Extract/Citral
1 Lycopene
1 Melatonin
1 Marjoram (Origanum majorana)
1 Piperlongumine
1 Sulforaphane (mainly Broccoli)
1 acetaminophen
1 Silymarin (Milk Thistle) silibinin
1 Wogonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:563  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page